Please login to the form below
STING
This page shows the latest STING news and features for those working in and with pharma, biotech and healthcare.
Bayer signs €250m pact with India’s Curadev for STING drugs
started working on STING drugs with potential in auto-immune and inflammatory diseases. ... Eli Lilly, for example, paid $12m upfront in a $620 million deal with Aduro Biotech at the end of 2018 for STING inhibitors, focusing on autoimmune diseases.
Latest news
-
AbbVie cures STING fever with Mavupharma acquisition
Novartis paid $200m upfront for rights to Aduro’s STING programme in 2015. ... pipeline. Meanwhile, Mavupharma isn’t the only company trying to develop small-molecule STING agonists.
-
Novartis bolsters anti-inflammatory R&D with $1.6bn IFM Tre buy
BMS’ interest was mainly on IFM’s STING and NLRP3 agonists and their potential in boosting immune responses to tumours.
-
New ‘voluntary’ UK pricing deal caps growth, but promises faster uptake
salve its sting.
-
Dynavax is ‘deal-ready’ after solid ESMO data; analyst
STING ‘has not stung’. Merck would be an obvious choice for that role, and the analysts also suggest that a deal for SD-101 could be more likely given a lacklustre ... also that the STING agonists were speculated to be more potent based on biology
-
A look ahead to key trial readouts at ESMO
Looking at some of the new mechanisms on show, Merck/MSD will also have the first clinical results for its STING activator MK-1454, Adaptimmune will have first-in-human results
More from news
Approximately 2 fully matching, plus 18 partially matching documents found.
Latest Intelligence
-
Cancer immunotherapy: What's on the horizon?
Among the plethora in the pipeline, Aurigene and BMS are looking at PD-1 inhibitors that can be dosed orally, Novartis, iTeos and Aduro are developing STING agonists that can
-
Live boulder, live louder
It’s like deconstructing a joke; by the end, the punchline loses its sting.
-
Medius Deal Watch table for March 2015
825. Aduro / Novartis. Licence and collaboration. Preclinical cancer immunotherapies targeting the STING (Stimulator of Interferon Genes) pathway.
-
Pharma deals in March 2015
One such example is Novartis which has CAR-T and checkpoint inhibitor programmes and has now added Aduro's STING (Stimulator of Interferon Genes) technology as an additional string to its ... bow. Aduro has a number of preclinical small molecule cyclic
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Frontera Group
STING - brand / diseases modules. PRECIS - clinical study modules.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- AstraZeneca and Innate Pharma to end study on immuno-oncology drug monalizumab
- AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval
- Regeneron terminates four clinical trials of its COVID-19 antibody cocktail REGEN-COV
- Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection
- Gilead announces positive Biktarvy data for HIV and hepatitis B
- Janssen announces positive results supporting Rybrevant and lazertinib combination treatment for NSCLC
- Medscape Education Receives Joint Accreditation with Commendation to Deliver Continuing Education for Healthcare Providers
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- Gilead Sciences set to acquire MiroBio in deal worth over $400m
- NHS England to roll out continuous glucose monitors to all those with type 1 diabetes
- Sanofi and Innovent Biologics to develop oncology drugs for patients in China
- WHO launches funding appeal for greater Horn of Africa prompted by food crisis
PMHub
Fishawack Health
Fishawack Health is the leading global commercialization partner for the modern life science era. Established in 2001 and headquartered in...
Latest intelligence
- Animation: Living With
- The journey from the patient's perspective...
- Achieving communication excellence by targeting the right channel at the right time
- By Danny Buckland...
- 6 trends shaping the future of personalized medicine
- Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
